The global Anthelmintic Drugs Market was valued at USD 4.30 Billion in 2022 and is projected to reach USD 6.92 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. The increasing prevalence of parasitic infections, especially in developing regions, is expected to drive the demand for anthelmintic drugs. The rising awareness about the health risks posed by parasitic infestations, coupled with growing efforts for the prevention and treatment of worm-related diseases, supports the market's expansion. Additionally, advancements in drug formulation and the increasing adoption of combination therapies are expected to further boost market growth in the coming years.
In addition, the rising incidence of soil-transmitted helminths (STH), malaria, and other parasitic diseases among both children and adults are key factors contributing to the market growth. The growing investments in the healthcare infrastructure of emerging economies, along with government initiatives focused on controlling parasitic infections, are likely to create new opportunities for market players. Furthermore, the increasing adoption of anthelmintic treatments in veterinary applications is also expected to positively influence market dynamics over the forecast period. The market is expected to witness a steady demand trajectory, driven by improved accessibility to effective treatment options.
Download Full PDF Sample Copy of Market Report @
Anthelmintic Drugs Market Research Sample Report
The Anthelmintic Drugs Market is primarily segmented by application into two categories: For Human and For Animal. The demand for anthelmintic drugs is critical to the treatment of parasitic worm infections, which remain a significant health concern worldwide. In the human segment, anthelmintics are used to treat a variety of parasitic worm infections, including roundworms, tapeworms, and hookworms. These infections can result in serious health complications, such as malnutrition, organ damage, and impaired physical and cognitive development. The growing prevalence of such diseases, particularly in developing countries, is driving the demand for anthelmintic drugs. As a result, pharmaceutical companies are focusing on developing effective, broad-spectrum anthelmintic drugs that can be used to treat multiple types of worm infestations in humans. Additionally, the rising awareness of the importance of deworming programs is also contributing to the market's growth in this segment.
For human applications, the use of anthelmintics spans various treatment regimens, including preventative deworming initiatives, particularly in regions where parasitic infections are endemic. The availability of generic versions of popular anthelmintic drugs is expanding access to treatment, thereby fueling growth in this segment. The increasing prevalence of parasitic worm infections in both children and adults has led to stronger governmental and non-governmental health programs aimed at controlling these diseases. Furthermore, innovations in drug formulations that minimize side effects and increase patient compliance are expected to contribute to the market's growth. As more people become aware of the risks associated with parasitic infections, particularly in tropical and subtropical regions, there is an increased demand for accessible and affordable anthelmintic drugs for human use.
The "For Human" subsegment of the Anthelmintic Drugs Market is driven by the need to treat parasitic infections that affect millions of people globally. Human worm infestations, such as ascariasis, trichuriasis, and strongyloidiasis, remain widespread, particularly in low-income regions. The use of anthelmintics in this subsegment is essential for managing these infections and preventing the further spread of parasitic diseases. The primary treatments involve drugs such as albendazole, mebendazole, and praziquantel, which are widely used for their effectiveness in treating various helminthic infections. Increasingly, pharmaceutical companies are focusing on developing novel drugs that are more targeted, effective, and have fewer side effects, addressing the growing demand for more efficient human anthelmintics.
In addition to the effectiveness of the drugs, there is a significant emphasis on the accessibility of anthelmintic treatments, especially in resource-limited settings where parasitic diseases are most prevalent. Governmental and non-governmental health organizations are promoting mass deworming programs, particularly for children, to reduce the burden of parasitic infections. These efforts are helping to boost the demand for anthelmintics in the human market. Furthermore, research is increasingly focusing on the development of combination therapies, which involve the use of multiple anthelmintic agents to treat complex infections more effectively. This research is critical in addressing the challenge of drug resistance, which can hinder the effectiveness of existing treatments in human populations.
The "For Animal" subsegment of the Anthelmintic Drugs Market focuses on the treatment and prevention of parasitic worm infections in animals, particularly in livestock, pets, and other animals used in agriculture. These infections, such as those caused by roundworms, tapeworms, and lungworms, can significantly impact the health and productivity of animals, leading to issues such as weight loss, reduced fertility, and even death in severe cases. Anthelmintic drugs are, therefore, a critical tool in veterinary care to ensure the well-being of animals and the safety of the food supply. The use of anthelmintics in this segment is essential for controlling parasitic diseases in both domestic and farm animals, which in turn contributes to improving animal husbandry and agricultural productivity.
The veterinary market for anthelmintic drugs is expanding due to increased awareness among animal owners about the importance of deworming and parasite control. Additionally, the growing demand for high-quality animal products, such as meat, milk, and eggs, is driving the need for effective parasitic control. Livestock farmers, in particular, are increasingly relying on modern anthelmintics that not only treat parasitic infections but also offer long-lasting protection against reinfection. In addition to traditional oral and injectable formulations, the market is seeing the rise of innovative delivery systems, such as medicated feed and boluses, which are designed to improve treatment compliance and reduce the labor involved in administering treatments. These trends highlight the growing importance of anthelmintic drugs in veterinary medicine and their role in maintaining the health of both domestic and farm animals.
Several key trends are currently shaping the anthelmintic drugs market, offering significant opportunities for growth. One of the most prominent trends is the increasing adoption of combination therapies, which involve the use of multiple anthelmintic agents to treat complex parasitic infections. This approach is expected to improve the efficacy of treatments, reduce the risk of resistance, and allow for more comprehensive care. As drug-resistant strains of parasites become more common, the development of novel combinations is becoming essential to ensure continued efficacy in treating human and animal worm infections. Pharmaceutical companies are investing heavily in research to discover new combinations of drugs that can target a broader range of parasites.
Another significant trend is the shift toward preventive care and deworming programs. Governments, non-governmental organizations, and health authorities are increasingly focusing on large-scale deworming initiatives to address parasitic infections in both humans and animals. This trend is particularly strong in regions where parasitic worm infestations are endemic, with public health programs providing access to anthelmintic treatments to reduce the burden of these diseases. Additionally, there is an opportunity for the market to expand in emerging economies, where rising awareness of parasitic infections is leading to increased demand for affordable and accessible anthelmintic treatments.
Technological advancements in drug delivery methods also present significant opportunities in the market. New drug formulations, such as sustained-release tablets, injectable treatments, and medicated feed for animals, are gaining popularity as they offer more convenience and better patient compliance. These innovations are particularly relevant in veterinary applications, where treating large groups of animals efficiently is a key concern for farmers and veterinarians. Furthermore, as the market becomes more competitive, companies are increasingly focusing on developing products that are not only effective but also cost-efficient, ensuring that treatments remain affordable for both human and animal populations.
1. What are anthelmintic drugs?
Anthelmintic drugs are medications used to treat parasitic worm infections, targeting and eliminating worms from the human or animal body.
2. How do anthelmintic drugs work?
These drugs work by either killing the parasitic worms or inhibiting their growth and reproduction, depending on the type of drug and parasite.
3. Are there any side effects associated with anthelmintic drugs?
Yes, while genera
For More Information or Query, Visit @ Anthelmintic Drugs Market Size And Forecast 2025-2030
Â